Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

The moves underscore growing competition with Danish rival Novo Nordisk A/S (NYSE:NVO) in the lucrative obesity drug market.

Starting in September, Lilly will raise the U.K. list price for Mounjaro’s highest monthly dose from 122 pounds to 330 pounds, a 170% jump, bringing it in line with prices in other European markets.

Also Read: How Novo Nordisk’s Weight-Loss Drug Could Unlock A Better Future For Biogen’s Alzheimer’s Treatment

Reuters reported that Eli Lilly initially set a lower price when Mounjaro launched in Britain in February 2024 to speed availability through the National Health Service (NHS).

Mounjaro competes directly with Novo ...